astegolimab (RG 6149) / Amgen, Roche 
Welcome,         Profile    Billing    Logout  
 18 Diseases   4 Trials   4 Trials   81 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
astegolimab (RG 6149) / Amgen, Roche
ARNASA, NCT05595642: A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Recruiting
3
1290
Europe, Canada, Japan, US, RoW
Astegolimab, Placebo
Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease (COPD)
06/25
06/25
NCT05878769: A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Recruiting
3
2000
Europe, Canada, US, RoW
Astegolimab
Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
06/27
06/27
2018-000919-24: A randomised placebo-controlled trial of anti-ST2 in COPD

Not yet recruiting
2
80
Europe
MSTT1041A (Anti-ST2), Ro 718-7807/F01, Solution for injection/infusion
University of Leicester, Genentech (San Francisco, CA)
Chronic Obstructive Pulmonary Disease (COPD), describes progressive lung diseases including emphysema, chronic bronchitis, with increasing breathlessness., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2018-003429-27: A Study to Assess the Efficacy and Safety of MSTT1041A in Patients with Moderate to Severe Atopic Dermatitis

Not yet recruiting
2
90
Europe
MSTT1041A, Ro 718-7807/F01-01, Solution for injection
Genentech Inc., Genentech Inc. c/o F. Hoffmann-La Roche Ltd
Moderate to severe atopic dermatitis, Atopic dermatitis (AD), is a type of inflammation of the skin (dermatitis) that results in itchy, red, swollen, and cracked skin, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05037929 / 2021-002045-15: A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Active, not recruiting
2
1440
Europe, Canada, US, RoW
Astegolimab, Placebo
Genentech, Inc.
Chronic Obstructive Pulmonary Disease
02/25
04/25
NCT06462118: A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects

Active, not recruiting
1
78
US
Astegolimab
Genentech, Inc.
Healthy Volunteers
04/25
04/25

Download Options